Last updated: February 24, 2026
What is NDC 00536-1186?
NDC 00536-1186 identifies Tecentriq (atezolizumab), an immunotherapy drug developed by Genentech (a Roche subsidiary). Approved for multiple cancer indications, including non-small cell lung cancer (NSCLC), small cell lung cancer, and urothelial carcinoma, Tecentriq represents a key agent in immune checkpoint inhibition.
Market Overview
Current Market Scope
The global oncology market exceeds $250 billion annually, with immune checkpoint inhibitors (ICIs) accounting for a significant share. Tecentriq competes primarily against drugs such as Keytruda (pembrolizumab, Merck) and Opdivo (nivolumab, Bristol-Myers Squibb).
Key indications for Tecentriq:
- Non-small cell lung carcinoma (NSCLC)
- Urothelial carcinoma
- Triple-negative breast cancer (TNBC)
- Small cell lung carcinoma (SCLC)
- Other solid tumors
Market Penetration and Adoption
Since its 2016 approval, Tecentriq's adoption has grown through:
- Broadening indications
- Favorable response rates in combination therapies
- Growing usage in first-line settings
In 2022, Tecentriq's sales reached approximately $2 billion globally, with North America accounting for over 70%, reflecting high uptake. Growth drivers include expanded indication approvals and combination regimens.
Competitive Landscape
| Drug |
Manufacturer |
Approved Indications |
Market Share (2022) |
List Price (per 1200 mg dose)a |
| Tecentriq |
Roche |
NSCLC, SCLC, others |
~20% |
~$9,850 |
| Keytruda |
Merck |
NSCLC, melanoma, others |
~50% |
~$11,650 |
| Opdivo |
Bristol-Myers Squibb |
NSCLC, melanoma, others |
~20% |
~$9,500 |
aPrices from SSR Health (2023).
Pricing Dynamics
Tecentriq's prices align with other ICIs, generally ranging from $8,500 to $12,000 per dose depending on the indication, dosage, and payer negotiations. No mandated discounts or pricing caps currently exist, but reimbursement rates and formulary placements influence final transaction prices.
Regulatory and Reimbursement Environment
- U.S. Medicare, Medicaid, and commercial insurers cover Tecentriq.
- Price negotiations are indirect and vary based on CMS policies, payer formularies, and negotiated discounts.
- Pricing strategies seek to balance accessibility, market penetration, and profit margins amid pressure on drug costs.
Price Projections
Short-term (1-2 years)
- Expect stability in list prices due to high demand and established reimbursement frameworks.
- No significant price reductions anticipated without generic or biosimilar competition, which is unlikely within the next 3-5 years given patent protections.
Medium-term (3-5 years)
- Potential for slight decreases (~5-10%) due to payer negotiations and volume discounts.
- Expansion into new indications and combination therapies will sustain revenue streams.
Long-term (5+ years)
- Introduction of biosimilars or alternative immunotherapies could pressure prices downward.
- Market saturation may lead to volume-driven revenue rather than price increases.
Revenue Growth Outlook
- Annual sales growth projected at approximately 8-12% driven by expanding indications, especially in early-line therapies.
- Regional expansion into emerging markets offers additional revenue opportunities but may involve price adjustments.
Key Considerations
- Patent exclusivity for Tecentriq extends until approximately 2027, delaying biosimilar competition.
- The evolving landscape of combination regimens (e.g., Tecentriq + chemotherapy) enhances sales potential.
- Price sensitivity varies across payer types; commercial payers tend to accept higher reimbursement levels than public programs.
Conclusion
Tecentriq maintains a strong market position with stable pricing, supported by expanding indications and clinical preferences. Price reductions are unlikely in the near term absent biosimilar entry. Revenue growth depends on indication expansion, regional penetration, and competitive dynamics.
Key Takeaways
- Tecentriq (NDC 00536-1186) is a leading immunotherapy with approximately $2 billion in 2022 sales.
- Its list price averages around $9,850 per 1200 mg dose; actual transaction prices vary based on negotiations.
- Competition from Keytruda and Opdivo dominates, but Tecentriq remains influential within multiple indications.
- Price projections suggest stability short-term, with slight declines possible in 3-5 years due to biosimilar and generic pressures.
- Market expansion into new indications and regions supports continued revenue growth.
FAQs
1. Will Tecentriq's price decrease upon biosimilar entry?
Yes; biosimilar competition expected around 2027 can lead to price reductions of 15-30%, similar to other biologics.
2. How does Tecentriq compare to Keytruda in pricing?
List prices are comparable, with Tecentriq typically around $9,850 for a 1200 mg dose versus $11,650 for Keytruda; actual prices depend on negotiations.
3. What factors could impact Tecentriq's future sales?
Introduction of biosimilars, new competing therapies, regulatory restrictions, and payer negotiations are primary factors.
4. Are there regional pricing differences?
Yes; prices are generally higher in North America and lower in emerging markets due to reimbursement structures.
5. What indications are most responsible for Tecentriq's revenue?
NSCLC and urothelial carcinoma are current primary revenue drivers, with expansion into other solid tumors aiding growth.
References
[1] SSR Health. (2023). Pricing and Cost Data for Oncology Drugs.
[2] IQVIA. (2022). Global Oncology Market Report.
[3] FDA. (2016). Approval Details for Tecentriq (atezolizumab).
[4] EvaluatePharma. (2023). Oncology Drug Market Outlook.
[5] CMS. (2023). Reimbursement Policies for Oncology Drugs.
